Xilio Therapeutics's three largest insider shareholders as of April 17, 2026 are Sciences, Inc. Gilead (TenPercentOwner, 9.11Mn shares), Impact Medicine Fund Lp Sv7 (TenPercentOwner, 3.23Mn shares), Capital Life Sciences Investors, Llc Bain (TenPercentOwner, 2.81Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Sciences, Inc. Gilead | - | 9,105,451 | 0 | 19 Dec, 2024 |
| Impact Medicine Fund Lp Sv7 | - | 1,613,632 | 1,613,632 | 03 Nov, 2021 |
| Capital Life Sciences Investors, Llc Bain | - | 0 | 2,805,413 | 10 Dec, 2021 |
| Capital Life Sciences Investors, Llc Bain | - | 0 | 2,805,413 | 10 Dec, 2021 |
| Venture Fund Xi, L.P. Atlas | - | 2,019,563 | 734,546 | 09 Feb, 2024 |
| James E Flynn | - | 0 | 2,287,944 | 28 Oct, 2021 |
| James E Flynn | - | 0 | 2,287,944 | 28 Oct, 2021 |
| James E Flynn | - | 0 | 2,287,944 | 28 Oct, 2021 |
| Llc Fmr | - | 0 | 1,907,670 | 28 Oct, 2021 |
| Pharmaceutical Co Ltd Takeda | - | 0 | 1,475,121 | 26 Oct, 2021 |
| Venture Fund Iv, L.P. Rivervest | - | 0 | 1,441,444 | 26 Oct, 2021 |
| Springs Capital Management Lp Rock | - | 0 | 1,256,472 | 26 Oct, 2021 |
| City Capital Llc Bay | - | 0 | 1,129,490 | 26 Oct, 2021 |
| Venture Fund Xi, L.P. Atlas | - | 0 | 735,942 | 26 Oct, 2021 |
| Kgaa Merck | - | 0 | 680,825 | 26 Oct, 2021 |
| Rene Russo | President And Ceo | 325,422 | 0 | 05 Jan, 2026 |
| Ltd Fil | - | 0 | 218,705 | 28 Oct, 2021 |
| Venture Investments, Llc Alexandria | - | 166,423 | 0 | 26 Oct, 2021 |
| Katarina Luptakova | Chief Medical Officer | 33,250 | 0 | 05 Jan, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 0 | 05 Jan, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 12,421 | 0 | 03 Jan, 2025 |
| James Samuel Shannon | - | 10,000 | 0 | 30 Mar, 2026 |
| Kevin M. Brennan | Svp, Finance And Accounting | 6,371 | 0 | 05 Jan, 2026 |
| Kevin M. Brennan | Svp, Finance And Accounting | 3,197 | 0 | 03 Jan, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 26 Mar, 2026 | James Samuel Shannon | Common Stock | A | 5,000 | $8.79 | 10,000 | D | P |
| 13 Feb, 2026 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 3,739,000 | $0.53 | 40,384,266 | D | P |
| 01 Jan, 2026 | Katarina Luptakova | Common Stock | A | 16,625 | - | 33,250 | D | M |
| 01 Jan, 2026 | Kevin M. Brennan | Common Stock | A | 5,000 | - | 8,197 | D | M |
| 01 Jan, 2026 | Rene Russo | Common Stock | A | 44,250 | - | 325,422 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Common Stock | A | 19,375 | - | 31,796 | D | M |
| 31 Dec, 2025 | Rene Russo | Stock Option (right to buy) | A | 1,500,258 | $0.00 | 1,500,258 | D | A |
| 31 Dec, 2025 | Katarina Luptakova | Stock Option (right to buy) | A | 451,885 | $0.00 | 451,885 | D | A |
| 02 Jan, 2026 | Kevin M. Brennan | Common Stock | D | 1,826 | $0.64 | 6,371 | D | S |
| 02 Jan, 2026 | Christopher James Frankenfield | Common Stock | D | 7,030 | $0.64 | 24,766 | D | S |
| 01 Jan, 2026 | Rene Russo | Restricted Stock Units | D | 44,250 | $0.00 | 88,500 | D | M |
| 31 Dec, 2025 | Christopher James Frankenfield | Stock Option (right to buy) | A | 668,789 | $0.00 | 668,789 | D | A |
| 01 Jan, 2026 | Katarina Luptakova | Restricted Stock Units | D | 16,625 | $0.00 | 33,250 | D | M |
| 31 Dec, 2025 | Kevin M. Brennan | Stock Option (right to buy) | A | 95,221 | $0.00 | 95,221 | D | A |
| 01 Jan, 2026 | Kevin M. Brennan | Restricted Stock Units | D | 5,000 | $0.00 | 10,000 | D | M |
| 01 Jan, 2026 | Christopher James Frankenfield | Restricted Stock Units | D | 19,375 | $0.00 | 38,750 | D | M |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Prefunded Warrants (right to buy) | A | 13,335,000 | $0.75 | 36,645,266 | D | X |
| 26 Nov, 2025 | Sciences, Inc. Gilead | Series B Warrants (right to buy) | D | 13,335,000 | $0.00 | 0 | D | X |
| 21 Nov, 2025 | Katarina Luptakova | Stock Option (right to buy) | A | 625,000 | $0.00 | 625,000 | D | A |
| 21 Nov, 2025 | Rene Russo | Stock Option (right to buy) | A | 2,075,000 | $0.00 | 2,075,000 | D | A |